FibroGen, Inc. (NASDAQ:FGEN – Get Free Report) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 5,300,000 shares, a growth of 79.7% from the February 13th total of 2,950,000 shares. Currently, 5.4% of the company’s stock are sold short. Based on an average trading volume of 3,330,000 shares, the short-interest ratio is presently 1.6 days.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Thursday, February 20th. StockNews.com assumed coverage on FibroGen in a research report on Friday. They issued a “hold” rating for the company.
Check Out Our Latest Stock Report on FGEN
Institutional Inflows and Outflows
FibroGen Trading Up 2.9 %
Shares of FGEN stock traded up $0.01 during trading on Friday, hitting $0.44. The company’s stock had a trading volume of 1,204,677 shares, compared to its average volume of 2,324,187. The business has a fifty day moving average of $0.51 and a 200-day moving average of $0.43. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80. The company has a market cap of $44.27 million, a PE ratio of -0.36 and a beta of 0.82.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Recommended Stories
- Five stocks we like better than FibroGen
- Expert Stock Trading Psychology Tips
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Bank Stocks – Best Bank Stocks to Invest In
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- P/E Ratio Calculation: How to Assess Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.